Comparative Pharmacology
Head-to-head clinical analysis: TERAZOL 7 versus VORICONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TERAZOL 7 versus VORICONAZOLE.
TERAZOL 7 vs VORICONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Terconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This disruption increases membrane permeability and leads to fungal cell death.
Inhibits fungal CYP450-dependent 14α-lanosterol demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Intravaginal: One full applicator (approximately 5 g of cream containing 40 mg of terconazole) inserted vaginally once daily at bedtime for 7 consecutive days.
Loading dose: 6 mg/kg IV every 12 hours for 2 doses, then maintenance 4 mg/kg IV every 12 hours; or 200–300 mg PO every 12 hours (400 mg PO every 12 hours for first 24 hours as loading dose if no IV).
None Documented
None Documented
Clinical Note
moderateVoriconazole + Tranilast
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast."
Clinical Note
moderateVoriconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tolfenamic acid."
Clinical Note
moderateVoriconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide."
Clinical Note
moderateTerminal elimination half-life is approximately 7-10 hours; clinically, it allows for once-daily vaginal application, but systemic accumulation is minimal with vaginal dosing.
The terminal elimination half-life is approximately 6 hours for CYP2C19 extensive metabolizers. In poor metabolizers (which occur in 15-20% of Asian populations), the half-life can be prolonged to up to 24 hours. Clinical context: Dosing adjustments may be necessary based on CYP2C19 genotype; the short half-life necessitates twice-daily dosing for most patients.
Primarily fecal (approximately 60%) as unchanged drug and metabolites; renal excretion accounts for about 20% (mostly metabolites).
Voriconazole is primarily metabolized in the liver via CYP2C19, CYP3A4, and to a lesser extent CYP2C9. Less than 2% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 20% of the dose, with the remainder as metabolites in urine. Overall, renal elimination of unchanged drug is negligible, but metabolites are excreted renally.
Category C
Category D/X
Azole Antifungal
Azole Antifungal
Voriconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronic acid."